The targeted therapy already has indications in acute myeloid leukemia. If approved, ivsosenib would be the first targeted therapy approved for patients with MDS who have a susceptible IDH1 mutation, ...
Credit: Getty Images. Findings showed an objective response rate of 83.3% with 38.9% of patients having a complete response. The Food and Drug Administration (FDA) has granted Priority Review for ...
Tibsovo is the first targeted therapy approved for this indication. The Food and Drug Administration (FDA) has approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or ...
The US Food and Drug Administration (FDA) has approved tablets of ivosidenib (Tibsovo, Servier Pharmaceuticals) for adults with isocitrate dehydrogenase (IDH)-1 mutated relapsed or refractory ...
A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions. This feature explains why a large group of different cancers ...
BOSTON, Oct. 24, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced the U.S. Food and Drug Administration (FDA) ...
Somatic monoallelic single nucleotide variants in the genes that encode isocitrate dehydrogenase (IDH) 1 and 2 are found in a large subset of diffusely infiltrating gliomas and subsets of acute ...
HOUSTON -- Progression-free survival (PFS) in IDH-mutant low-grade glioma remained twice as high in adults who received vorasidenib (Voranigo) after surgery versus placebo, according to a follow-up ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback